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Abstract
Aims: Previous genome-wide linkage analysis has suggested that chromosomal region 17p13.3 may harbour genes
influencing left ventricular mass (LVM) in man. To date, the genetic factors accounting for LVM variability remain largely
unknown but a non-coding RNA gene within this region, micro-RNA 22 (miR-22), has been implicated in cardiac hypertrophy
and heart failure in animal models. We thus investigated the relationship between common genetic polymorphisms
surrounding miR-22 and left ventricular mass in a family-based association study.
Methods and Results: We studied a cohort of 255 families comprising 1,425 individuals ascertained via a hypertensive
proband. Ten single nucleotide polymorphisms which together tagged common genetic variation surrounding the miR-22
gene were genotyped. There was evidence of association between the rs7223247 polymorphism, which lies within the
39UTR of a gene of unknown function, TLCD2, immediately downstream from miR-22, and left ventricular mass determined
by Sokolow-Lyon voltage (Bonferroni corrected p-value = 0.038). The T allele at rs7223247 was associated with an 0.272
standard deviation higher Sokolow-Lyon voltage. Genotype was responsible for ,1% of the population variability in LVM.
Conclusions: Genotype at the rs7223247 polymorphism affects left ventricular mass determined by Sokolow-Lyon voltage.
The neighbouring genes miR-22 and TLCD2 are strong candidates to account for this observation.
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Introduction
Left ventricular hypertrophy is a strong independent predictor
of cardiovascular morbidity and mortality. Left ventricular mass
(LVM) measured using either the electrocardiogram (ECG) or by
echocardiography has substantial heritability [1], but thus far the
genes responsible involved remain largely unidentified. LVM
measured using a heritable electrocardiographic derivative,
Sokolow-Lyon voltage (SLV; obtained by summation of the S-
wave voltage in ECG lead V1 and the R-wave voltage in lead V5)
is an independent predictor of mortality [2]. Previous evidence
from a family-based study suggested genetic linkage of ECG-
voltage derived LVM to chromosomal region 17p13.3 (LOD
score = 2.67; p= 0.0002) [3].
MicroRNAs (miRNAs) are a group of small non-coding RNA
molecules involved in posttranscriptional gene regulation. During
the last ten years many miRNAs have been identified as major
regulators of cardiac hypertrophy [4,5]. Within rat cardiomyo-
cytes, phenotypic screening identified microRNA 22 (miR-22),
which is located within the region of 17p13 showing linkage to
LVM in man, as a pro-hypertrophic modulating miRNA [6–8].
Gain of function mouse models support a role for miR-22 as a
mediator of LV hypertrophy traits in cardiac myocytes [8].
Interestingly, the recently implicated LVM human gene, osteogly-
cin was identified as a downstream target of miR-22 mediating
cardiac fibroblast activation [9,10]. Moreover, targeted deletion of
miR-22 sensitizes mice to cardiac decompensation and LV
dilatation when subjected to pressure overload [8]. miR-22 is
therefore a strong candidate gene influencing LVM variation in
man.
miR-22 lies within the 59 untranslated region of the open reading
frame C17orf91, and is flanked by the expressed genes Tram-Lag-
CLN8 domain 2 (TLCD2) and WD repeat 81 (WDR81) at
chromosome 17p13.3 (Figure 1). The TLCD2 gene codes for a 264
amino acid long helical transmembrane protein, which belongs to
a large family of genes containing a Tram-Lag-CLN8 domain.
The function of TLCD2 is unknown, however it has been
postulated that it may have a role in both lipid metabolism and
ceramide synthesis [11]. Genes associated with these pathways
have previously been implicated in the development of cardiac
hypertrophy and its consequences [12]; for example ceramide
accumulation contributes to heart failure in patients with cardiac
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hypertrophy [13–15]. Thus, TLCD2 is also a candidate gene
possibly influencing LVM in the linked region of 17p13.3.WDR81
encodes a multi-domain transmembrane protein predominantly
expressed in the brain. Mutations in the gene are associated with
autosomal recessive cerebellar ataxia and other neurological
conditions. Since these conditions are not associated with left
ventricular hypertrophy, WDR81 is a less strong candidate in the
region than TCLD2 and miR-22.
We conducted an association study of SNPs tagging common
genetic variation in miR-22 and TCLD2 in a cohort of families
ascertained via a proband with hypertension and phenotyped for
LVM. This cohort had previously shown evidence of genetic
linkage of LVM to the miR-22/TCLD2 region; candidate-gene
based fine-mapping within linked regions is an accepted strategy to
discover genetic associations with complex diseases [16].
Methods
Ethics Statement
Written informed consentwas obtained fromall participants prior
to enrolment. The study was approved by the Central Oxford
Research Ethics Committee and Newcastle and North Tyneside
Local Research Ethics Committee. The study was conducted
according to the principles of the Declaration of Helsinki.
Cohort Ascertainment and Phenotyping
Between 1993–1996 two hundred and forty-eight British
Caucasian families were collected for a quantitative genetic
investigation of LVM and other cardiovascular risk factors as
previously described [17]. In summary, families were identified
through essential hypertensive probands, categorised within the
upper 5% of the population. Patients with secondary hypertension
were excluded. Stringent inclusion criteria were employed.
Suitable patients required daytime ambulatory blood pressure
readings exceeding 140 mmHg systolic and 90 mmHg diastolic; or
three clinic blood pressure measurements greater than 160/
95 mmHg; or receiving treatment with a minimum of two
antihypertensive drugs. Enrolment within the study cohort was
conditional on appropriate family structure. Where one parent of
the sibship was available to give blood for DNA analysis, families
required at least three siblings clinically assessable for blood
pressure measurement. Where no parent was available for DNA
analysis, families required at least four assessable siblings.
Quantitatively assessed sibships were recruited either in the
generation of the proband or his/her offspring. If individuals
from the sibship were classified as being hypertensive, spouses and
offspring of the hypetensive sibs were also collected. Employing
this recruitment strategy resulted in mainly nuclear families and
some extended families, as previously described [18].
Participants underwent 24 hour ambulatory blood pressure
monitoring, using the A&D TM2421 monitor according to a
previously described protocol [19]. Detailed medical and lifestyle
histories were recorded alongside anthropometric measurements
of height, weight, waist and hip circumferences, using standard
methods [20]. DNA was extracted from blood samples using
standard methods. Families were recalled for additional cardio-
vascular phenotyping in 1999–2001, where resting 12-lead
electrocardiographic measurements were recorded and SLV (S
Figure 1. SNPs at the miR-22 locus. All SNP locations are indicated by lines on the miR-22 schematic (17p13.3/30.0 kb) derived from the UCSC
genome browser (http://www.genome.ucsc.edu/). The Haploview output is directly related to the schematic, with the linkage disequilibrium
relationships between HapMap Phase 3 SNPs in the region shown, indicating the three principal haplotype blocks. Darker squares represent higher R-
squared between markers. rs7223247 is circled in red. SNPs chosen for genotyping (at threshold MAF=0.05, r2 = 0.8) are enclosed within green boxes.
doi:10.1371/journal.pone.0055061.g001
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wave in V1 + R wave in V5) calculations performed according to
standard protocols previously described [21]. As previously
reported, LVM measured by electrocardiography in the cohort
was higher than previously reported in the unselected general
population, indiciating that our proxy selection for increased LVM
through familial hypertension was successful [22].
Genotyping
Tag SNPs within the miR-22/TCLD2 region (615 kb to
incorporate flanking transcriptional regulating sites) were identi-
fied with reference to phase 3 HapMap CEU data (http://www.
hapmap.org). Three major haplotype blocks existed within the
region. The Tagger utility, within Haploview version 4.2,
identified ten tag SNPs (Inclusion criteria: Hardy-Weinberg p-
value cutoff = 0.001, minimum genotype = 75%, Mendelian er-
rors = 0.05, minimum minor allele frequency = 0.05, r2 = 0.8). The
LD pattern and location of SNPs in the region is shown in Figure 1.
Multiplex genotyping was completed for 8 SNPs using Sequenom
iPLEX. Validated Applied BiosciencesTM TaqManH SNP geno-
typing assays were implemented for 2 remaining SNPs using the
Applied BioscienceTM 7900 HT fast RT-PCR system. Allelic
discrimination algorithms were implemented to analyse data using
Applied BioscienceTM SDS v2.3 software; with automatic
genotype calls manually altered appropriately. Genotyping was
carried out blinded to phenotypic information.
Statistical Analysis
PEDSTATS was employed to determine Mendelian inheritance
of all the genotypes, and Hardy-Weinberg equilibrium for each
marker [23]. Phenotypes were assessed for Normality. All variables
required log-transformation to adequately conform to a Normal
distribution (P.0.05). Phenotypes were adjusted for the significant
covariates, including age, systolic BP, weight, waist-hip ratio and
height using multiple step-wise linear regression, as previously
described [24]. Normalised residual values underwent quantitative
trait genetic association analysis, implemented using MERLIN
version 1.1.2 [25]. This approach allows consideration of shared
polygenic effects shared between family members. FASTSNP
(http://fastsnp.ibms.sinica.edu.tw) was utilised to determine the
functional relevance of identified SNPs. We corrected our p-values
for multiple testing using a Bonferroni approach; although this is
likely over-conservative, such an approach seemed appropriate
given the somewhat limited size of our cohort and lack of a
replication cohort ascertained according to the same protocol.
Results
A total of 1,425 subjects from 248 families were recruited to the
study (of whom 45.5% were male and 38.6% hypertensive). The
median family consisted of 5 subjects. In total, 60% of families
comprised between 4 and 6 genotyped and phenotyped members.
71% of families consisted of 2 generations, with remaining families
consisting of 3 generations. 16% of families contained assessable
sibships only in the proband’s offspring; in the remaining 84%
there was an assessable sibship within the proband’s generation.
The second phase of cardiovascular phenotyping, requiring
electrocardiogram assessment, was completed in 955 family
members (449 men and 506 women), 67% of the total cohort.
Subjects with structural heart disease on echocardiography
(N= 69) and with electrocardiographic abnormalities consistent
with previous myocardial infarction (N=18) were excluded from
analysis, delivering a sample of 868 eligible subjects for the genetic
analyses. On average, excluded subjects were older, more likely to
be hypertensive, diabetic and male. 224 families (395 men and 473
women) were included in the electrocardiographic analyses. The
demographics of the population are shown in Table 1.
The ten SNPs were successfully genotyped in 95.7% 61.61
participants, with no departures from Hardy-Weinberg equilibri-
um at the 5% significance level and high concordance of the
observed allele frequencies with those reported in the HapMap
CEU population (www.hapmap.org) (Table S1). The estimated
genotype error rate was ,1%. The rs7223247 SNP, in the fourth
exon of the TLCD2 gene, had a minor allele frequency of 0.078 in
our total population. The major allele of this SNP is guanine (G)
and the minor allele is thymidine (T). Data on ECG, genotype,
and all significant covariates included in the final model were
present in 708 individuals. The genotype at this SNP was
significantly associated with the log-transformed, covariate-adjust-
ed residual Sokolow-Lyon voltage (Table 2). In view of the small
number of T/T homozygotes we combined G/T and T/T
individuals in the association analyses (that is, a dominant genetic
model). The T allele was associated with a higher SLV derived
LVM (P=0.0038) (Table 2). Carriers of the T allele had a 0.272
standard deviation higher LVM by SLV. The fitted model implies
a 9% difference in the untransformed values between the lowest
and highest value genotypes. The genotype of rs7223247
accounted for approximately 1% of the total LVM variance.
Following post-test Bonferroni correction (correcting for the 10
genotyped SNPs), rs7223247 remained significantly associated
with SLV derived LVM (P=0.038).
Discussion
We have shown that genotype at the rs7223247 SNP in the
TLCD2 gene neighbouring miR-22 contributes to the variance of
left ventricular mass measured by SLV on the ECG. The major G
allele at this SNP is associated with lower values of LVM. Carriers
of the minor allele had ,10% higher LVM than non-carriers, and
genotype accounted for ,1% of the population variability in
LVM. The rs7223247 SNP is situated in exon 4 of the TLCD2
gene. TLCD2 has four exons, and is transcribed on the reverse
strand of chromosome 17. The mRNA transcript produced is
625 bp in length, and is entirely derived from a segment of exon 4
that is slightly 39 (in the direction of transcription) to rs7223247.
TLCD2 has been hypothesised to be involved in ceramide
Table 1. Characteristics of the study population (n = 868).
Characteristic Value
Male, n (%) 395 (45.5)
Age in years, mean (6SD) 52.4 (13.5)
Systolic BP, mean in mmHg (6SD) 137 (21)
Hypertension, n (%) 349 (42.3)
Antihypertensive treatment, n (%) 330 (40.0)
*ECG LVH, n (%) 86 (9.9)
Diabetes, n (%) 21 (2.4)
Weight, mean in kg (6SD) 76.8 (14.7)
Height, mean in m (6SD) 1.68 (0.1)
Body mass index, mean in kg/m2 (6SD) 27.1 (4.8)
Waist-hip-ratio (6SD) 0.87 (0.1)
*ECG left ventricular hypertrophy based on any one of the following criteria:
Sokolow-Lyon voltage .35 mm; RaVL .11 mm; Cornell voltage .28 mm in
men and .20 mm in women; Cornell product .0.24 mV ms.
doi:10.1371/journal.pone.0055061.t001
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synthesis and lipid metabolism, which has been associated with
cardiac metabolism and may contribute towards cardiac hyper-
trophy [26]. rs7223247 is a synonymous SNP, with no obvious
involvement in splicing or transcription factor binding. Functional
studies will be required to clarify if rs7223247 is associated with
quantitative differences in levels of TLCD2 transcription that may
in turn be related to variance in LVM, which appears to be the
most likely mechanism for the association. An alternative
explanation is a cis-acting effect of rs7223247 on miR-22
expression. Although previous studies have demonstrated that
SNPs within the pre-miR region can influence miR expression
[27,28], fewer data are available in respect of more distant eQTLs
influencing miR expression. Further studies will be required to
investigate whether rs7223247 genotype has a cis-acting effect
altering miR-22 expression [29].
Multiple hypothesis driven candidate gene studies have
investigated LVM previously; however, hypothesis-generating
genome-wide association studies (GWAS) are the most compre-
hensive method of evaluating the genetic effects on LVM.
However, results from GWAS focused on LVM have so far been
disappointing. A previous echocardiography-based GWAS con-
ducted by Vasan et al. investigated 12,612 individuals, but
demonstrated no locus affecting LVM at genome-wide significance
[30]. This contradicts recent findings reported by Shah et al. who
demonstrated, in a large candidate gene study, 4 loci within
10,256 individuals contributing towards ECG derived LVM [31].
A much smaller Korean GWAS conducted by Hong et al.
reported 14 SNPs from 8 genetic loci to be associated with ECG-
LVM [32]; however, none of these correlate with the regions
detected in the analyses by Shah et al. Our focused investigation of
candidate genes within a linked region may be considered
complementary to these GWAS approaches. The region of
chromosome 17 where miR-22 is located has not been significantly
associated (p,1025) with ECG LVM in these previous studies.
Differences between studies may be explained in part due to the
recruitment strategy. Our cohort represents a collection of families
recruited via a proband within the upper 5% of the blood pressure
distribution and incorporated additional hypertensive individuals
in extending nuclear pedigrees. It is thus dissimilar to previous
studies, as a third of participants were classified within the upper
5% tail of the blood pressure distribution and overall the
prevalence of left ventricular hypertrophy was 30% higher in
our cohort compared, for example, with the community-
ascertained cohorts studied by Vasan et al. [30]. Moreover, our
previous work has shown higher heritability for ECG derived
measures of LVM than for echo derived measures; and typically
regions showing association with echocardiographic and electro-
cardiographic LVM have shown little overlap. Taken together,
these considerations should increase our power to detect genetic
effects related to LVM. However, these hypothesis-generating
findings require replication in additional cohorts. Indeed, it would
be useful to analyse rs7223247 genotypes within additional cohorts
enriched for high blood pressure (or otherwise selected for higher
LVM) in future studies.
The conclusions drawn from this study are fully supported by
electrocardiographic data, derived from detailed phenotyping
methods, accounting for potential confounding variables.The
current studydoes howeverhave certain limitations.Asweemployed
stringent selection criteria, results may not be generalizable for
familieswhoarenot genetically ‘‘loaded’’ for hypertension.Although
significant covariates were adjusted for, anti-hypertensive medica-
tions were not specifically adjusted for, which may have a minor
confounding effect. It is known that ECG is not the most sensitive
method for recordingLVMand future studies enrollinghypertensive
patients may derive benefit from utilising magnetic resonance
imaging to further investigate this associationwith superiorprecision.
In summary, we have shown a significant effect of the
rs7223247 SNP in the TLCD2/miR-22 region and LVM, in
hypertensive families. From a clinical perspective, the magnitude
of the association we have described is too small to have any role in
genetic risk stratification, for example to guide treatment decisions
in patients with borderline hypertension. However, genes in our
region of association may be therapeutic targets for preventing
cardiac hypertrophy in the context of hypertension.
Supporting Information
Table S1 SNPs neighbouring miR-22 genotyped in family
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